Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
暂无分享,去创建一个
T. Curiel | M. Rebelatto | N. Segal | A. Gupta | Sunil Sharma | Z. Wainberg | P. O’Donnell | A. Drakaki | O. Hamid | J. Luke | M. Gordon | C. Massard | R. Sanborn | Xiaoping Jin | J. A. Blake-Haskins | W. Tan | J. Kurland | S. Rafii | G. Colón-Otero
[1] M. McCarter,et al. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[2] R. Bourgon,et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.
[3] C. Drake,et al. New Strategies in Bladder Cancer: A Second Coming for Immunotherapy , 2015, Clinical Cancer Research.
[4] Roland L Dunbrack,et al. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. , 2015, European urology.
[5] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[6] E. Garon. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. , 2015, Seminars in oncology.
[7] M. Atkins,et al. Toxicities of Immunotherapy for the Practitioner. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] K. Steele,et al. Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients. , 2015 .
[9] N. De Brucker,et al. Immunotherapy for non-small-cell lung cancer: the past 10 years. , 2015, Future oncology.
[10] T. Powles. Immunotherapy: The development of immunotherapy in urothelial bladder cancer , 2015, Nature Reviews Clinical Oncology.
[11] F. Cappuzzo,et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.
[12] J. Wolchok,et al. Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] P. Hegde,et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.
[14] L. Malik. Immunotherapy for Bladder Cancer: Changing the Landscape , 2014 .
[15] N. Segal,et al. 1058PDA PHASE I MULTI-ARM DOSE-EXPANSION STUDY OF THE ANTI-PROGRAMMED CELL DEATH-LIGAND-1 (PD-L1) ANTIBODY MEDI4736: PRELIMINARY DATA. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] N. Segal,et al. 988PDCLINICAL ACTIVITY AND SAFETY OF MEDI4736, AN ANTI-PD-L1 ANTIBODY, IN PATIENTS WITH HEAD AND NECK CANCER. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] N. Segal,et al. A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors. , 2014 .
[18] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[19] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .
[20] Loise M. Francisco,et al. The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.
[21] S. Culine,et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[23] Lieping Chen,et al. Inhibitory B7-family molecules in the tumour microenvironment , 2008, Nature Reviews Immunology.
[24] G. Freeman,et al. PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.
[25] Yoshimasa Tanaka,et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.
[26] L. Collette,et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. , 2006, European journal of cancer.
[27] Sergio Ricci,et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] S. Ricci,et al. Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer , 2005 .
[29] P. Albers,et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Stewart,et al. The National Cancer Data Base report on bladder carcinoma , 1996, Cancer.
[31] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[32] Daan Brandenbarg. The National. , 1892 .